Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia
A Quintás-Cardama, J Cortes - Clinical Cancer Research, 2008 - AACR
Despite the efficacy of imatinib therapy in chronic myelogenous leukemia, the development
of resistance continues to challenge the treatment of this disease. Mutations within the …
of resistance continues to challenge the treatment of this disease. Mutations within the …
Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia
A Quintás-Cardama, J Cortes - Clinical Cancer Research, 2008 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Despite the efficacy of imatinib therapy in
chronic myelogenous leukemia, the development of resistance continues to challenge the …
chronic myelogenous leukemia, the development of resistance continues to challenge the …
Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia
A Quintás-Cardama, J Cortes - Clinical Cancer …, 2008 - mdanderson.elsevierpure.com
Despite the efficacy of imatinib therapy in chronic myelogenous leukemia, the development
of resistance continues to challenge the treatment of this disease. Mutations within the …
of resistance continues to challenge the treatment of this disease. Mutations within the …
Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia.
A Quintás-Cardama, J Cortes - … Research: an Official Journal of the …, 2008 - europepmc.org
Despite the efficacy of imatinib therapy in chronic myelogenous leukemia, the development
of resistance continues to challenge the treatment of this disease. Mutations within the …
of resistance continues to challenge the treatment of this disease. Mutations within the …
Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia
A Quintás-Cardama, J Cortes - Clinical Cancer …, 2008 - augusta.elsevierpure.com
Despite the efficacy of imatinib therapy in chronic myelogenous leukemia, the development
of resistance continues to challenge the treatment of this disease. Mutations within the …
of resistance continues to challenge the treatment of this disease. Mutations within the …
Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia
A Quintás-Cardama, J Cortes - … cancer research: an …, 2008 - pubmed.ncbi.nlm.nih.gov
Despite the efficacy of imatinib therapy in chronic myelogenous leukemia, the development
of resistance continues to challenge the treatment of this disease. Mutations within the …
of resistance continues to challenge the treatment of this disease. Mutations within the …